Literature DB >> 18395080

Immune response against frameshift-induced neopeptides in HNPCC patients and healthy HNPCC mutation carriers.

Yvette Schwitalle1, Matthias Kloor, Susanne Eiermann, Michael Linnebacher, Peter Kienle, Hanns Peter Knaebel, Mirjam Tariverdian, Axel Benner, Magnus von Knebel Doeberitz.   

Abstract

BACKGROUND & AIMS: Colorectal cancers (CRC) associated with the hereditary nonpolyposis colorectal cancer (HNPCC) syndrome display high-level microsatellite instability (MSI-H) as a consequence of mismatch repair deficiency. HNPCC-associated CRC frequently show features of a pronounced immune response, most likely resulting from the MSI-induced generation of novel tumor-specific carboxy-terminal frameshift peptides (FSPs). However, the role of FSP-specific immune surveillance mechanisms in HNPCC are unknown at present.
METHODS: The efficacy of tumor-infiltrating T cells isolated from MSI-H CRCs (n = 3) was examined by in vitro killing assays. FSP-specific T-cell responses were measured by enzyme-linked immunospot in the peripheral blood from patients with MSI-H CRC (n = 32), healthy HNPCC mutation carriers (n = 16), patients with microsatellite stable (MSS) CRC (n = 17), and healthy donors (n = 22).
RESULTS: Tumor-infiltrating T cells isolated from MSI-H CRCs specifically recognized MSI-induced FSPs and showed cytotoxic activity against MSI-H but not MSS CRC cells. FSP-specific T-cell responses were detected in the majority of peripheral blood samples from patients with MSI-H but not MSS CRC. Interestingly, FSP-specific T-cell reactivity was already detectable in the peripheral blood of healthy HNPCC family members with germline mutations but without history of tumor development.
CONCLUSIONS: These data suggest that FSPs presented by DNA mismatch repair-deficient CRC cells are effectively recognized by the patient's immune system and may explain the characteristic clinicopathologic features of HNPCC-associated but also sporadic MSI-H CRCs. These observations are of high relevance for the development of FSP-based vaccination approaches, particularly for the preventive application in HNPCC mutation carriers.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18395080     DOI: 10.1053/j.gastro.2008.01.015

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  143 in total

Review 1.  Tumour-infiltrating T-cell subsets, molecular changes in colorectal cancer, and prognosis: cohort study and literature review.

Authors:  Katsuhiko Nosho; Yoshifumi Baba; Noriko Tanaka; Kaori Shima; Marika Hayashi; Jeffrey A Meyerhardt; Edward Giovannucci; Glenn Dranoff; Charles S Fuchs; Shuji Ogino
Journal:  J Pathol       Date:  2010-12       Impact factor: 7.996

2.  Somatic mutations of the coding microsatellites within the beta-2-microglobulin gene in mismatch repair-deficient colorectal cancers and adenomas.

Authors:  Mark Clendenning; Alvin Huang; Harindra Jayasekara; Marie Lorans; Susan Preston; Neil O'Callaghan; Bernard J Pope; Finlay A Macrae; Ingrid M Winship; Roger L Milne; Graham G Giles; Dallas R English; John L Hopper; Aung K Win; Mark A Jenkins; Melissa C Southey; Christophe Rosty; Daniel D Buchanan
Journal:  Fam Cancer       Date:  2018-01       Impact factor: 2.375

Review 3.  Recent advances in Lynch syndrome.

Authors:  Leah H Biller; Sapna Syngal; Matthew B Yurgelun
Journal:  Fam Cancer       Date:  2019-04       Impact factor: 2.375

4.  Leveraging premalignant biology for immune-based cancer prevention.

Authors:  Avrum Spira; Mary L Disis; John T Schiller; Eduardo Vilar; Timothy R Rebbeck; Rafael Bejar; Trey Ideker; Janine Arts; Matthew B Yurgelun; Jill P Mesirov; Anjana Rao; Judy Garber; Elizabeth M Jaffee; Scott M Lippman
Journal:  Proc Natl Acad Sci U S A       Date:  2016-09-16       Impact factor: 11.205

5.  Cellular vaccination of MLH1-/- mice - an immunotherapeutic proof of concept study.

Authors:  Claudia Maletzki; Yvonne Saara Gladbach; Mohamed Hamed; Georg Fuellen; Marie-Luise Semmler; Jan Stenzel; Michael Linnebacher
Journal:  Oncoimmunology       Date:  2017-12-14       Impact factor: 8.110

Review 6.  Clinical significance of microsatellite instability in colorectal cancer.

Authors:  Matthias Kloor; Laura Staffa; Aysel Ahadova; Magnus von Knebel Doeberitz
Journal:  Langenbecks Arch Surg       Date:  2013-09-19       Impact factor: 3.445

7.  Tumor characteristics as an analytic tool for classifying genetic variants of uncertain clinical significance.

Authors:  Robert M W Hofstra; Amanda B Spurdle; Diana Eccles; William D Foulkes; Niels de Wind; Nicoline Hoogerbrugge; Frans B L Hogervorst
Journal:  Hum Mutat       Date:  2008-11       Impact factor: 4.878

8.  Lack of HLA class II antigen expression in microsatellite unstable colorectal carcinomas is caused by mutations in HLA class II regulatory genes.

Authors:  Sara Michel; Michael Linnebacher; Joshua Alcaniz; Maike Voss; Rudolf Wagner; Wolfgang Dippold; Christina Becker; Magnus von Knebel Doeberitz; Soldano Ferrone; Matthias Kloor
Journal:  Int J Cancer       Date:  2010-08-15       Impact factor: 7.396

Review 9.  [Molecular pathogenesis. Its importance in targeted therapy in colorectal cancer].

Authors:  M Kloor; S Michel; M von Knebel Doeberitz
Journal:  Pathologe       Date:  2008-11       Impact factor: 1.011

10.  Serum antibodies against frameshift peptides in microsatellite unstable colorectal cancer patients with Lynch syndrome.

Authors:  Miriam Reuschenbach; Matthias Kloor; Monika Morak; Nicolas Wentzensen; Anja Germann; Yvette Garbe; Mirjam Tariverdian; Peter Findeisen; Michael Neumaier; Elke Holinski-Feder; Magnus von Knebel Doeberitz
Journal:  Fam Cancer       Date:  2010-06       Impact factor: 2.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.